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Abstract Medical advances have led to a welcome increase
in life expectancy. However, accompanying longevity intro-
duces new challenges: increases in age-related diseases and
associated reductions in quality of life. The loss of skeletal
tissue that can accompany trauma, injury, disease or advanc-
ing years can result in significant morbidity and significant
socio-economic cost and emphasise the need for new, more
reliable skeletal regeneration strategies. To address the unmet
need for bone augmentation, tissue engineering and regener-
ative medicine have come to the fore in recent years with new
approaches for de novo skeletal tissue formation. Typically,
these approaches seek to harness stem cells, innovative scaf-
folds and biological factors that promise enhanced and more
reliable bone formation strategies to improve the quality of life
for many. This review provides an overview of recent devel-
opments in bone tissue engineering focusing on skeletal stem
cells, vascular development, bone formation and the transla-
tion from preclinical in vivo models to clinical delivery.
Keywords Skeletal stem cell . Osteoprogenitor .
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Introduction
The loss or dysfunction of skeletal tissue that can accompany
trauma, injury, disease or advancing years can result in significant
morbidity as well as a variety of socio-economic issues. In addi-
tion, changing patient demographics, together with rising patient
expectations and increasing complexity of ensuing clinical sce-
narios, provide the imperative for new, more reliable skeletal
regeneration strategies. Current approaches to replace or restore
significant quantities of lost skeletal tissue come with substantial
limitations and inherent disadvantages that may be harmful. Tis-
sue engineering and regenerative medicine have come to the fore
in recent years with new approaches for de novo skeletal tissue
formation in an attempt to address the unmet need for bone
augmentation and skeletal repair. These approaches seek to har-
ness stem cells, innovative scaffolds and biological factors to
create, ideally, robust, reproducible and enhanced bone formation
strategies to improve the quality of life for an ageing population.
The following reviews recent developments in bone tissue engi-
neering and regeneration, focusing on skeletal stem cells, vascu-
lar development and bone formation. In addition, we review
current developments in the translation from preclinical in vivo
models to clinical delivery. We detail current regenerative strate-
gies in development to augment bone formation in a range of
orthopaedic scenarios including examination of some of the
translational issues before patient treatment, much heralded, can
be routinely achieved.
Skeletal Stem Cells
The remarkable ability of bone to remodel, coupled with the
capacity of bone tissue to heal/regenerate following fracture,
supports the concept of a stem cell population within postnatal
bone marrow. Typically, bone marrow comprises the stromal
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and haematopoietic compartments, and the existence of a
haematopoietic stem cell (HSC) population has long been ac-
knowledged. Bone marrow cell suspensions include both
haematopoietic cells and non-haematopoietic stromal cells.
The stromal tissue functions as a scaffold, composed of a
network of cells that provide physical and functional support
to the haematopoietic cells. The stromal fraction, characteris-
tically, are able to adhere to tissue culture plastic, while the
non-adherent haematopoietic cells can be readily removed
from the adherent stromal cell cultures by a simple wash step.
Seminal experiments by Alexander Friedenstein and co-
workers were instrumental in demonstrating that a culture of
bone marrow stromal cells, at clonal density, enabled identifica-
tion of cells, referred to as colony-forming units-fibroblastic
(CFU-Fs), which were capable of establishing clonal growth in
a density-independent fashion [1]. Furthermore, Friedenstein and
colleagues established unequivocally that bone marrow stromal
tissue and the derived clonogenic fraction could generate bone
following in vivo transplantation. Since multiple tissues, such as
bone, cartilage and fat, were identified in heterotopic transplants
of cell populations originating from a single stromal cell, it was
concluded that osteogenic, chondrogenic and adipogenic pheno-
types were part of a multilineage system downstream of the
common progenitor cell population retained in postnatal bone
marrow stroma. This multipotent stromal progenitor cell popula-
tion constituted a second type of stem cell population, in addition
to HSCs, within bone marrow referred to as the osteogenic
(Friedenstein) or stromal (Owen and Friedenstein) or mesenchy-
mal (Caplan and Pittenger) or skeletal (Bianco and Robey) stem
cell population [1, 2].
An array of cell-surface antigens, namely the trypsin-
resistant antigen recognised by the STRO-1 antibody, CD29
(β1 subunit of integrin family), CD44 (glycoprotein
expressed by both HSCs and mesenchymal stem cells
(MSCs)), CD49a (laminin and collagen receptor VLA-α1),
CD73 (ecto-5′-nucleotidase), CD90 (Thy-1), CD105
(Endoglin), CD106 (VCAM-1), CD146 (MCAM), CD166
(ALCAM) and CD271 (low-affinity nerve growth factor re-
ceptor), are expressed by skeletal stem cells (SSCs). These
markers have been used to enrich for the skeletal stem cells
from a heterogeneous bone marrow mononuclear cell fraction
using a positive immunoselection strategy [3•]. Alternatively,
SSC en r i chmen t can be ach i eved by nega t i ve
immunoselection for haematopoietic cell-surface antigens
such as CD34, CD45, CD19, CD14, CD11b, CD79α and
HLA-DR surface molecules [3•]. However, the lack of con-
sensus on the exact nature of cell-surface marker/s unique to
SSCs, a spectrum of ‘stemness’ within the SSC population
due to variable expression of certain markers and the inherent
variation in biological systems highlight the difficulty in de-
fining a unique SSC signature. Thus, the absence of a specific
SSC marker has contributed, in part, to conflicting data within
the literature on the characteristics of the SSC.
A widely accepted perspective, championed by Paolo
Bianco and co-workers, advocates that the SSC population
is a precisely defined physical and conceptual entity, which
resides in a subendothelial position in the perivascular spaces
surrounding the vascular sinusoids/distinctive venous vessels
occurring in bone marrow [4••]. The researchers observed
that, upon transplantation in vivo, the SSC was capable of
generating a complete heterotopic bone or bone marrow
organ/ossicle (including a compartment of perivascular stro-
mal cells with similar phenotypes and properties as the origi-
nally explanted cell) in which haematopoiesis from the recip-
ient animal was established. Thus, as demonstrated by Bianco
and co-workers, the ability to establish, organise and transfer
the haematopoietic niche in vivo is an important defining fea-
ture of SSCs. In contrast, a view proposed by Mark Pittenger
and Arnold Caplan characterises MSCs as products of their
environment, and it is possible to develop this environment
in vitro [5]. Thus, in accordance with this view, MSCs can
adopt two phenotypes: (i) a ‘constitutive’ phenotype in which,
as perivascular cells, the population expresses the characteris-
tic cell-surface markers both in vivo and ex vivo and demon-
strates functionality through its multipotential ex vivo differ-
entiation capabilities, and (ii) a ‘regulatory’ phenotype in sit-
uations of tissue/vessel damage in vivo, where the released
pericytes are activated by injury to become MSCs that then
serve as site-regulated, multidrug dispensaries to promote and
support the natural regeneration of focal injuries [6•].
The pleiotropic effects of SSCs on cells of the immune
system have been extensively detailed in the literature, and
SSCs are often regarded as immune privileged or non-immu-
nogenic, given their phenotype is widely described as MHC
class I+, MHC class II−, CD40−, CD80− and CD86− [6•,
7–10]. However, before the full therapeutic potential of this
adult stem cell population can be realised, rigorous studies in
defined in vivo systems are needed to elucidate the precise
identity of the regulatory effects of SSCs on immune and
inflammatory cells. Critically, the successful application of
SSCs in bone regeneration strategies necessitates the develop-
ment of simple, safe and efficacious culture techniques that
allow ex vivo expansion of SSCs without loss of their func-
tional, immunophenotypic and cytogenetic characteristics.
Development of such protocols in combination with strategies
for robust osteogenic differentiation of human SSCs (typical-
ly, through the application of factors, hormones, supplements)
and incorporation of smart matrices/scaffolds auger well for
bone tissue formation [11].
Scaffold Matrices for Bone Regeneration
The concept of a biomaterial has been defined as ‘a substance
that has been engineered to take a formwhich is used to direct,
by control of interactions with components of living systems,
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the course of any therapeutic or diagnostic procedure’ [12].
The scaffold provides the extracellular microenvironment for
the support and stimulation of stem/cell-driven tissue regener-
ation serving as a supportive platform for transplanted cells or
recruiting and retaining endogenous cells together with appro-
priate mechanical cues and biological triggers. Approaches in
biomaterials are driven by a desire to replace the structural
aspect of a diseased tissue or organ and to trigger/harness
regenerative processes capable of restoration of functional bi-
ology. To perform such functions, biofunctionalisation and
tissue integration together with appropriate degradation char-
acteristics in the absence of any significant adverse reactions
are important attributes in biomaterial development for clini-
cal application.
Awealth of materials are in development and indeed already
exist that seek to incorporate physical, chemical and biological
signalling cues, to create appropriate regenerative host micro-
environments, in an attempt to aid the healing/regenerative pro-
cesses. These include scaffolds such as (i) bioceramics—incor-
porating hydroxyapatite or calcium phosphates that typically
exhibit good bone integration, are osteoconductive and display
a high compressive strength; (ii) natural polymers, such as
extracellular matrix proteins (e.g. collagens, fibrin, elastin, al-
ginate, hyaluronic acid) and xenogeneic derived materials, are
intrinsically biocompatible and have reached clinical use with
minimal adverse immunological reports; (iii) synthetic
polymers—a variety of macromolecules (e.g. polyethylene gly-
col (PEG)) modulated on the basis of their monomer constitu-
ents, the relative ratios of co-polymers and the interactions/
functionalisation of polymer side chains creating a raft of ma-
terials for tissue engineering; and (iv) hydrogels—hydrated
polymer chains, offer significant potential in the delivery of
cells and growth factors [13]. These materials can typically
support the adhesion of cells and other ECM proteins, enable
migration of cells and facilitate incorporation of bioactive mol-
ecules and nutrients and their subsequent controlled, in time
and space, targeted release. In recent studies from Dawson
et al., a synthetic clay hydrogel was shown to be suitable for
delivery through injection (with subsequent gel network self-
reassembly) of growth factors and cells and to be capable of
stimulating in vivo angiogenesis [14••].
An area that has seen significant development is additive
manufacturing (AM), the computer-directed process of 3D
layer-by-layer model fabrication [15]. AM offers the potential
for fabrication of implants of exquisite complexity that could
range from permanent to biodegradable, with a potential in-
termediate ability to be incorporated into the host bone tissue.
Despite recent advances, the usual issues/challenges, as for all
current largematerial constructs of vascularisation, integration
and, to date, economic viability remain. Thus, while current
technological developments in the biomaterials field create an
exciting environment enabling further rapid progress, clinical
translation of experimental findings remains limited.
Development of Vascularised Bone
Establishment of a blood vessel network by vasculogenesis
and angiogenesis is essential for cellular gaseous exchange,
nutrient supply and waste product removal during new tissue
formation. There is significant emerging evidence that blood
vessels act as a reservoir for an undifferentiated skeletal pro-
genitor that translocates with new vessel ingrowth to areas of
tissue damage and repair. Furthermore, the interaction be-
tween inflammatory cues, cellular components and vascular
elements is a highly intricate, spatiotemporal event essential in
bone tissue repair. It is therefore not surprising that the com-
plex biochemical and physical associations between skeletal
cells and neighbouring blood vessels have been identified as
an essential requisite for dynamic bone development and re-
pair. Thus, insufficient or incongruous vascularisation of bone
will ultimately result in irregular bone formation, delayed
union or non-union of bone fractures [16, 17]. Hence, the
regeneration of a functional vascular supply concomitantly
with bone osteogenesis is central to the regeneration of func-
tional bone in, for example, critical-sized skeletal defects.
The essential molecular crosstalk between endothelial cells
and skeletal progenitor cells in osteogenesis have been inves-
tigated using pharmacological, molecular and biochemical
studies to identify the factors that are the predominant players
in this coupling [16, 17]. These include vascular endothelial
growth factor (VEGF), fibroblast growth factor (FGF), pla-
cental growth factor (PGF), the angiopoietins (ANG 1 and
2), transforming growth factor (TGF) superfamily (BMP-2,
BMP-7, BMP-9, TGF-β), receptor activator of nuclear factor
kappa ligand (RANKL), biglycans and endothelin-1 [16, 17].
Furthermore, recent studies have identified microRNAs to af-
fect fracture repair. As well as the predicted and targeted cy-
tokines and growth factors, modulation of tissue and cellular
oxygen gradients has emerged as key determinants in angio-
genesis resulting in profound effects on bone. Furthermore,
inhibition of VEGF receptors on skeletal progenitor popula-
tions (osterix-CRE) has been implicated in the reduction of
trabecular bone [16, 17].
The vasculature has come to the fore in bone biology in
recent years with the concept advanced and evidenced that the
pericyte cell (encompass microvessels or vessel adventitial
cells) is the potential precursor for the skeletal stem cell, cen-
tral in bone repair [18]. Furthermore, bone stem cells of the
bone marrow have been found to reside in the perivasculature
and the detection of these cells using the nestin-GFP transgene
demonstrated expression of both pericyte markers alpha
smooth muscle actin (αSMA) and NG2. Mediators such as
DJ-1 (a 189-amino acid protein encoded by PARK7) which
modulates FGF receptor 1 signalling activation and glycopro-
tein non-metastatic melanoma protein B (GPNMB) have been
identified in the complex cross communication between vas-
cular and osteogenic cells during bone regeneration. Notch
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signalling has now been shown to induce proliferation of en-
dothelial cells in postnatal long bone, and interestingly, the
disruption of Notch signalling in a specific sub-population
of endothelial cells affected skeletal bone properties together
with impaired angiogenesis [19, 20••].
There is no doubt therapeutic targeting of angiogenesis
to treat non-healing bone defects will be essential for im-
proved clinical skeletal outcomes. Treatments such as
erythropoietin (EPO) have been used to provide a good
effect given the potential of EPO to induce cartilaginous
callus formation and angiogenesis resulting in enhanced
endochondral ossification. Vascular factors are also integral
in other skeletal repair targets such as distraction osteogen-
esis or the repair of hypoplastic facial bone defects. Thus,
key is the development of the appropriate balance of bone
and blood vessel integration in what are tightly temporally
and spatially regulated systems. Creation of bioengineered
heterotopic bone around new blood vessels as suggested by
Cai and colleagues and altering the levels of growth factors
such as VEGF and BMP-2 to modulate bone repair [21•] is
an interesting suggestion to enhance bone augmentation.
Undoubtedly, the development of new vascular ingrowth
therapies will dramatically help in the application of bone
cellular constructs in augmenting bone repair.
Development of In Vivo Models of Bone Repair
Awealth of in vitro data over the last four decades has eluci-
dated invaluable information on the molecular and cellular
mechanisms involved in osteogenic repair, and the more re-
cent development of complex, multicellular, three-
dimensional models has significantly enhanced our under-
standing of osteogenesis and bone healing. However, these
techniques remain unable to mimic the cellular, molecular,
physiological and biomechanical intricacies present at the
whole organism level. Critical aspects in bone repair such as
the presence of a patent vascular network and biomechanical
stimulation have proven difficult to reproduce outside of the
living organism and to date necessitate the application appro-
priate in vivo approaches. Similarly, a number of factors in-
fluence appropriate animal use and in vivo design (Table 1),
and thus, the translational development of novel therapies in
bone repair and fracture healing requires, typically a continu-
um of in vivomodelling, progressing through initial feasibility
studies into clinically relevant translational models.
Reconstitution of the multifaceted and complex system in-
volved in bone repair in an experimental in vivo environment
needs to ensure inclusive examination of all processes in-
volved. Table 2 summarises common in vivo skeletal models,
a number can be seen to overlap, while ‘mechanistic’ models
detail in vivo models that aim to simulate clinical application
representing end-user specific systems in translational
research.
Small Animal Models
Small animal preclinical models of bone repair have proved
efficacious in the assessment of biomaterial and cellular per-
formance providing information on localised and systemic
toxicity, tumourigenesis, cytological and biological compati-
bility, vascular integration and potentially deleterious off-
target effects. Models include the application of complete
and partial osteotomies of long bones, calvaria, sternum and
hip bones as well as sub-cutaneous and intramuscular implan-
tation. The use of mouse, rat and rabbit animal models, rela-
tively accessible to the researcher, allows analysis of bone
regeneration and repair in relatively short time frames and
with, as required, robust animal numbers. The sub-cutaneous
model involves a simple full thickness skin incision under
aseptic conditions and subsequent evaluation of a number of
implants in a single animal providing data within a period of
time varying from days to months on vascular compatibility
and bone regeneration simultaneously using contrast-
enhanced micro-computed tomography (μ-CT) supplemented
by traditional histological techniques. The ectopic nature of
this model limits evaluation of bone augmentation in a native
bone environment and necessitates the development of bone-
specific models such as the calvarial and femoral segmental
models. While small animal models are cost effective, acces-
sible and offer useful information on biological performance,
such approaches are restricted by the scale and limited clinical
relevance and, therefore, a need for large animal models.
Large Animal Models
The design of large animal models typically develops from
either a scaled up small animal model or adaptation of a model
based on a human clinical need. The former can be exempli-
fied by long- and flat-bone defects with or without a form of
mechanical fixation. The latter are as variable as the clinical
targets and typically utilise species of comparable human bio-
mechanical and physiological composition, predominantly in
the pig and sheep (comprehensively reviewed by Gothard
et al. [32•]). Large animal models allow the assessment of
large volume repair over a longer time frame sufficient to
examine remodelling and implant integration. Models such
as spinal fusion, hip/knee arthroplasty and fixator develop-
ment are clinically analogous and therefore offer insight into
the development of treatment options. The advent of new
emerging therapies, such as growth factor and small osteogen-
ic molecule delivery, are an exciting move towards minimally
invasive treatment options of bone disease and repair. As
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treatment modalities encompass not only engineered scaffolds
and implants but also biochemical and molecular interven-
tions, the match/mismatch between animal and human phys-
iology will remain central with variations in gene and protein
sequence homology presenting the potential for misrepresen-
tative data from in vivo models. Conversely, the wealth of
genetic and therapeutic data from small animal studies offers
exciting new avenues when harnessed with cell- and scaffold-
based modalities for bone augmentation.
Clinical Translation
In harnessing regenerative and tissue engineering strategies,
the requirements of a tissue engineering solution are very
much dependent upon the clinical scenario. A clinical issue
such as tibial atrophic non-union may require only stimulation
of fracture healing, whereas other bone repair situations may
require merely mechanical support. In contrast, segmental
bone defects typically require the provision of vascularised
bone with the ability to integrate to the surrounding tissues
and thus present a significant challenge. The following high-
light relatively recent developments on the application of tis-
sue engineering strategies in the management of fractures,
arthrodesis, osteochondral defects and segmental bone
defects.
Fractures and Arthrodesis Over a decade ago, BMP was
delivered using a collagen sponge within a cage device (In-
fuse, Medtronic) or collagen putty (OP-1, Stryker) to mediate
spinal arthrodesis and fracture healing. While initial results
were promising, subsequent cases and clinical reports have
demonstrated that the high doses of BMP used together with
poor growth factor localisation culminated in osteolysis and
Table 1 Selection and design of in vivo animal models
In vivo species and breed selection criteria Considerations for in vivo model design
• Size and anatomical characteristics
• Biomechanical characteristics
• Physiological similarity to humans
• Gene sequence and protein homology to humans
• Genetic variability between cohorts
• Availability
• Husbandry and handling, risk to staff
• Housing requirements
• Resistance to disease and environmental stress
• Lifespan and life-stage progression throughout study duration
• Existence of anaesthetic, surgical and post-operative protocols
• Robust nature, tolerant of experimental model
• Surgical survivability
• Ethical and societal implications
• Model design addresses the research question
• Develop model to improve data relevance
• Modification to eliminate procedural shortcomings of previous techniques to
address shortcomings
• Occur after completed in vitro toxicity, cytocompatibility and efficacy assays
• In vitro feasibility justifies use of animal model
• Study group design, including appropriate controls
• Adequate group numbers, avoiding excessive animal use
• Avoid wasteful experimental duplication
• Impact of model on animal behaviour
• Model design closely simulates possible clinical usage
• Consider methods of post-experimental analysis
Table 2 Summary of common animal models in musculoskeletal research and systems assessed
System assessed Model description Common species Relevant publications
Vascular Chorioallantoic membrane (CAM) model,
sub-cutaneous and intramuscular implantation
Chick egg and embryo, mouse, rat,
rabbit, humanised animal models
Nowak-Sliwinska,
P et al. 2014 [22]
Smith, EL et al. 2013 [23••]
Intramembranous
ossification
Partial and full thickness cranial defects,
uni-cortical long bone defects, hip and
sternal defects
Mouse, rat, rabbit, goat, pig, sheep Yamano, S et al. 2014 [24]
Endochondral
ossification
Ectopic models, sub-cutaneous and intramuscular
implantation, long bone defect models
Mouse, rat, rabbit, dog, goat,
mini-pig, pig, sheep, primate
Shim, JH et al. 2014 [25]
Berner et al. 2013 [26]
Suarez-Gonzalez,
D et al. 2014 [27]
Mechanistic Spinal Fusion, dental implantation, distraction
osteogenesis, orthopaedic and dental device
implants, metabolic, neoplastic and infectious
disease models, molecular targeted healing
Rat, rabbit, dog, goat, mini-pig,
pig, sheep, cow and horse,
primate, human
Ke, HZ et al. 2012 [28]
Monroea, D et al. 2012 [29]
Oheim, R et al. 2013 [30•]
Brodano, GB et al. 2014 [31]
Relevant publications have been selected to introduce the most recent advances in surgical design, scaffold production, factor delivery and molecular
intervention, comprehensively reviewed in Gothard, D et al. [32•]
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heterotopic ossification [33]. Furthermore, to date, there re-
mains controversy as to the clinical effectiveness of BMP in
the treatment of open tibial fractures [34]. Ceramic bone graft,
when used in combination with fresh autologous bonemarrow
aspirate, has been shown to be safe and as effective as autol-
ogous bone grafting (ABG) in stimulating some forms of spi-
nal fusion [35, 36]. Interestingly, while the addition of an
osteoinductive material appears to be a prerequisite for spinal
fusion, there is emergent data demonstrating calcium phos-
phate cement application could produce outcomes equivalent
to ABG in the management of tibial plateau fractures [37].
Furthermore, a case series has shown that ceramic graft use
in impaction bone grafting of the acetabulum produced good
medium-term results. In support of such observations,
Damron and colleagues have shown the addition of bone mar-
row aspirate to ceramic graft applied to treat benign bone
cavity defects provided no added advantage (Damron et al.)
[38] with ceramic bone alone sufficient to produce healing.
Osteochondral DefectsOsteochondral defects in the knee
are typically managed through the application of
microfracture, or autologous chondrocyte implantation,
a two-stage surgical procedure [39]. Synthetic multi-
phasic scaffolds, without additional cells or growth fac-
tors, have been used clinically to treat osteochondral
defects; however, their efficacy remains to be demon-
strated in a randomised controlled trial [40]. An alterna-
tive therapy has been developed in which autologous
articular chondrocytes are harvested, seeded upon a syn-
thetic scaffold material and applied to the defect in a
single procedure [41]. Initial results appear promising;
however, while this technique avoids a second surgical
procedure, it does involve articular chondrocyte harvest,
and to date, the long-term outcome remains unknown.
Initial results appear promising; however, while this
technique avoids a second surgical procedure, the ap-
proach involves articular chondrocyte harvest, and to
date, the long-term outcome remains unknown. Areas
of current exploration for osteochondral defect treatment
include application of chondroprogenitor cells from retro
patella or sub-cutaneous adipose tissue in combination
with printed scaffolds generated using additive
manufacturing in a single surgical procedure [15].
Bone Defects Segmental bone defects are most commonly
found in the tibia and result in amputation if structural integ-
rity cannot be restored and maintained. Current treatment
strategies include the application of (i) isolated ABG, (ii)
vascularised ABG, (iii) induced membrane technique
(Masquelet) with ABG and (iv) bone transport procedures.
Karger and colleagues and Meinig and co-workers have com-
bined synthetic bone and membrane material with ABG in
post-traumatic and bone defect reconstructions using the
induced membrane technique [42, 43]. BMP-2 combined with
allograft has been shown to be as effective as ABG in the
management of diaphyseal tibial cortical defects [44]. Current
studies include application of stem-progenitor cell-seeded
scaffolds [45•] and variations on the Masquelet technique
using a synthetic bioabsorbable angiogenic and osteogenic
membrane [46] with synthetic and autograft materials. To
date, the development of a mechanically robust, vascularised
bone construct providing an integrated tissue engineering so-
lution for segmental bone defects remains to be clinically
translated (Fig. 1).
The use of cell-based therapies in skeletal regenera-
tive medicine is an area of current intense research fo-
cus. The efficacy of current approaches has yielded am-
biguous results with limited consensus on the most ef-
fective cell origin type, number, combination and meth-
od of delivery. In the majority of current experimental
models, the introduction of a cell progenitor source,
alone or in combination with biomaterials, typically
has occurred at the time of wound creation, with cells
immediately localised in vivo into an acute inflammato-
ry physiological environment. During the initial phases
of tissue trauma, the affected tissue is rich in cyto-
modulatory peptides including TNF-α, interleukins and
interferons as well as raised serum acute-phase protein
concentrations. Typically, within the tissue engineering/
regenerative community, it has been thought that the
effectiveness of stem and progenitor populations intro-
duced into such a perceived hostile inflammatory milieu
is inhibitory/detrimental to tissue reparation. However,
recent studies using spatiotemporal manipulation of cell
delivery, specifically, delayed injection of cells into a
wound site, after the acute inflammatory response sub-
sides has generated exciting results experimentally in
the fields of segmental bone tissue engineering [47•],
cardiology [48] and neuronal repair [49]. Delayed injec-
tion experimental models utilising readily accessible
adult-derived bone marrow stromal cells have shown
enhanced repair of damaged tissue compared to ‘time-
of-trauma’ cell applications. It is evident that the means
and timing of cell delivery influence treatment efficacy.
Enhanced reparation is observed when cells are intro-
duced sub-cutaneously, intravenously as well as directly
to the wound site [47•, 48–50]. Critically, the advan-
tages noted experimentally have been realised in ortho-
paedics [51] and prospectively offer effective advanced
cell-based treatment modalities in regenerative medicine
Future Perspectives
To date, SSC therapy is hampered predominantly by our
limited understanding of skeletal stem cell fate,
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immuno-phenotype and selection criteria. There is a
need for facile, safe and efficacious protocols of stem
cell isolation and expansion together with enhanced bio-
informatics knowledge on the phenotypic ‘fingerprint’
of the skeletal stem cell at a single-cell resolution and
the generation of skeletal cells from pluripotent stem
cell sources. It is likely new cell approaches and the
development of ‘smart’ hydrogels, able to temporally
and spatially control growth factor release to render safe
and efficacious growth factor use in stimulation of frac-
ture healing and arthrodesis, are areas that will see sig-
nificant development. The next 5 to 10 years will see
intense interest in the potential of additive manufacture
to produce synthetic multiphasic scaffolds in which the
internal architecture and topography are analysed for
cartilage and bone regeneration requirements. It is likely
approaches will include the development and integration
of immuno-privileged constructs containing an appropri-
ate scaffold/growth factor(s) composition for autologous
and, potentially, allogeneic skeletal populations. For rou-
tine and, critically, robust bone formation approaches,
the future challenge for regenerative medicine will be
the development of bioengineered vascularised grafts at
appropriate scale for clinical application.
Conclusions
The relative accessibility of an autologous osteoprogenitor
population has driven the application of skeletal stem cell
therapy for orthopaedic application in contrast to other stem
cell sources (pluripotent embryonic stem cells or adult stem
cell populations from connective tissues).
For cell-based clinical application of skeletal popula-
tions to be realised, simple and robust isolation together
with safe and efficacious delivery approaches as well as
defined in vivo systems will be key that ensure mainte-
nance of cell function, immuno-phenotype and cytoge-
netic characteristics. Work continues apace in a number
of groups to generate matrices that will permit temporal-
spatial growth factor release with seeded stem cells to
promote prevascularised prior to application as well as
vascularised bone constructs. While the treatment of
large segmental bone defects remains a significant chal-
lenge with successful repair or the integration of large
regenerative tissue constructs critically dependent on de-
velopment of a functioning blood supply, nevertheless,
these are exciting times in skeletal regenerative medi-
cine with significant new approaches emerging for bone
repair for an increasing ageing demographic.
Fig. 1 Skeletal tissue
engineering in the clinic. Clinical
skeletal repair requirements: (i)
cartilage regeneration, (ii) bone
void filling, (iii) stimulation of
fracture healing or arthrodesis and
(iv) reconstruction of segmental
bone loss are represented in
different quadrants. (i) In the top
right quadrant are arthroscopic
images of an osteochondral lesion
(upper) and chondral lesion post
microfracture (lower). (ii) In the
lower right quadrant is a 3D
reconstruction (upper) and
radiograph (lower) of a patient
with severe osteoarthritis and
protrusio acetabuli. (iii) In the
lower left quadrant show
radiographs demonstrating
fracture non-union and spinal
arthrodesis. (iv) In the top left
quadrant demonstrates a
comminuted tibial fracture
(upper) and segmental bone
defect (lower). Current treatment
strategies are detailed (in red) in
corresponding triangles
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